Biocon Limited announced on August 18, 2026, that its U.S. subsidiary received supplemental approval from the Food and Drug Administration (FDA) for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjectors. The regulatory nod covers two dosage strengths: 45 mg/0.5 ml and 90 mg/ml. This development expands the delivery formats available for the drug, which was originally approved by the U.S. FDA on November 29, 2024.

The autoinjector format is designed to support tailored treatment approaches across various care settings and patient needs. By offering a self-administered option, the company aims to improve accessibility for patients managing chronic autoimmune conditions.

Approved dosage strengths

The supplemental approval covers the following delivery configurations:

Therapeutic indications

Yesintek is indicated for the treatment of several autoimmune conditions affecting adult and pediatric patients aged 6 years and older. The approved indications include:

• Moderate to severe plaque psoriasis
• Active psoriatic arthritis
• Moderate to severely active Crohn's disease in adults
• Ulcerative colitis in adults

Portfolio impact

This supplemental approval strengthens Biocon's immunology product portfolio in the United States. The move reaffirms the company's strategy to improve access to affordable medicines globally by diversifying delivery mechanisms for existing therapies.

Biocon Limited shareholders approved a final dividend of ₹0.50 per equity share and appointed S.R. Batliboi & Associates LLP as statutory auditors at its 48th Annual General Meeting (AGM) held on August 06, 2026. While routine governance resolutions passed with near-unanimous support, the proposed Biocon Unity Long Term Incentive Plan 2026 faced significant resistance from public institutions, with over 51% of their votes cast against the measure. This divergence highlights a split between promoter confidence and institutional caution regarding future equity dilution and management compensation structures.

The meeting, conducted via video conferencing, saw participation from 90 shareholders (2 promoters, 88 public). The scrutinizer’s report, submitted by Pradeep B Kulkarni of V Sreedharan & Associates on August 08, 2026, confirmed compliance with Section 108 of the Companies Act, 2013, and SEBI Listing Regulations. Voting rights were reckoned as of July 30, 2026, with remote e-voting open from August 01 to August 05, 2026.

Resolution Outcomes

The Board placed nine resolutions before members. Ordinary resolutions concerning financial statements, dividends, director reappointment, and auditor appointments passed with overwhelming support. However, the special resolutions related to the employee incentive scheme revealed a sharp divide among public institutional investors.

Institutional Dissent on Incentive Plans

The most material development was the rejection of the Biocon Unity Long Term Incentive Plan 2026 by public institutions. For Resolution 5 (formulation of the plan), public institutions voted 48.88% in favor and 51.12% against. Similarly, for Resolution 7 (authorization for secondary acquisition by the Biocon India Limited Employees Welfare Trust), institutions voted 49.32% in favor and 50.68% against.

In contrast, promoter group shareholders voted unanimously (100%) in favor of all resolutions, including the incentive plans. Public non-institutional shareholders also supported the plans, with over 99.99% approval rates. The dissent appears concentrated solely among large institutional investors, who may be concerned about the potential dilution or cost implications of the performance stock units, restricted stock units, and management stock units outlined in the plan.

Governance and Strategic Context

S.R. Batliboi & Associates LLP was appointed as statutory auditors for a five-year term, succeeding B S R & Co. LLP. Eric Vivek Mazumdar was reappointed as a director liable to retire by rotation. Executive Chairperson Kiran Mazumdar-Shaw had previously reported that operating revenues grew by 13% in FY26, driven by the biosimilars segment. The company recently consolidated Biocon Biologics as a wholly owned subsidiary and raised nearly US$1 billion through QIPs to strengthen its balance sheet.

What the Numbers Show

The stark contrast between promoter support (100%) and institutional opposition (>51%) on the incentive plans suggests a divergence in views on capital allocation and executive compensation. While promoters view the long-term incentive plan as critical for retaining talent in a competitive biosimilars market, institutional investors may perceive the equity-based incentives as dilutive or misaligned with immediate shareholder returns. This dissent is notable given the company’s recent strategic consolidation and revenue growth, indicating that investors are closely monitoring how management aligns its interests with broader shareholder value beyond operational metrics.